Antiplatelet drugs also known as blood thinners, are commonly used to inhibit platelet activation and reduce the risk of blood clots. The key indication for these drugs is in the prevention and treatment of cardiovascular diseases including myocardial infarction, stroke, and peripheral arterial disease. Antiplatelet drugs act by blocking the ADP pathway, which is a key player in platelet activation and aggregation. Common antiplatelet drugs include clopidogrel, aspirin, prasugrel, ticagrelor, etc. which are used singly or in combination for patients with cardiovascular conditions.
The global antiplatelet drugs market is estimated to be valued at US$ 2674.22 Bn in 2024 and is expected to exhibit a CAGR of 12% over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights.
Market Dynamics:
Increase in Cardiovascular Diseases: As per the WHO, cardiovascular diseases are the major cause of death globally, taking an estimated 17.9 million lives each year. Many developing and developed nations are experiencing significant rise in lifestyle diseases like diabetes and obesity, which increases the risk of cardiovascular events like heart attacks and strokes. With growing incidence of heart attacks, strokes and related medical disorders, the demand for antiplatelet drugs for prevention and treatment is expected to see strong growth during the forecast period.
Opportunity for Combination Therapies: Current clinical research trends indicate higher efficacy of combination antiplatelet therapies involving two different drug classes simultaneously, as compared to monotherapies. For instance, aspirin in combination with newer P2Y12 receptor inhibitors like ticagrelor and prasugrel is now recommended over clopidogrel- aspirin combination for acute coronary syndrome. Emergence of novel combinations tailored for high risk patients can further expand the antiplatelet drug market size.
Segment Analysis
The antiplatelet drugs market can be segmented on the basis of drug type, therapeutic application, route of administration, and distribution channels. By drug type, the market is dominated by aspirin which accounts for around 45% share owing to its low-cost and easy availability. The aspirin segment is followed by adenosine diphosphate (ADP) receptor inhibitors, phosphodiesterase inhibitors, and glycoprotein IIb/IIIa inhibitors. By therapeutic application, the largest segment is cardiovascular diseases as antiplatelet drugs are widely used to prevent heart attacks and strokes. In terms of route of administration, the oral route dominates the market as antiplatelet drugs are majorly available and prescribed in oral forms like tablets and capsules. The distribution channel analysis indicates that hospital pharmacies and retail pharmacies collectively account for around 65% share of the total antiplatelet drugs market.
Pest Analysis
Political: Governments across countries are focusing on increasing healthcare access and budgets which is favoring the growth of antiplatelet drugs market. However, stringent regulations for drug approval can act as a barrier.
Economic: Rising income levels and growing healthcare spending is driving the antiplatelet drugs demand especially in developing countries. The high treatment costs of cardiovascular diseases also make antiplatelet drugs an integral part of overall disease management.
Social: Growing geriatric population which is more prone to CVDs along with changing lifestyle habits leading to increased obesity and diabetes are major social factors augmenting the antiplatelet drugs adoption. Moreover, rising health awareness too supports market growth.
Technological: Companies are investing in R&D to develop novel antiplatelet drugs with better efficacy and safety profiles. They are also developing drug delivery systems for enhanced bioavailability and patient compliance like extended-release formulations.
Key Takeaways
The global antiplatelet drugs market share is expected to witness high growth over the forecast period. The global antiplatelet drugs market is estimated to be valued at US$ 2674.22 Bn in 2024 and is expected to exhibit a CAGR of 12% over the forecast period 2024 to 2031.
North America is expected to hold around 35% share of the global antiplatelet drugs market through 2031 owing to ongoing presence of major market players and availability of advanced healthcare facilities. Asia Pacific is projected to grow at the fastest rate during the forecast period ascribed to rising geriatric population, growing healthcare infrastructure in countries like China and India, and lowering regulatory norms.
Key players related content comprises: Key players operating in the antiplatelet drugs market are Chang Chun Group, Covestro AG, Dow, Hexion, and Evonik. Among these, Covestro AG and Dow collectively account for over 20% market share attributed to their diversified product portfolios and strong distribution networks globally.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it